Oncology
Cancer clinical trials
Studies of cancers and tumors of every type and site, from prevention to treatment. We’re tracking 20,349 recruiting studies in this area right now.
By phase
- Not applicable9,620
- Phase 24,438
- Phase 12,681
- Phase 1/Phase 21,656
- Phase 31,399
- Phase 2/Phase 3286
- Phase 4269
Top conditions
- Breast Cancer1,208
- Prostate Cancer649
- Cancer634
- Colorectal Cancer475
- Lung Cancer420
- Ovarian Cancer342
- Multiple Myeloma327
- Pancreatic Cancer288
- Gastric Cancer284
- Acute Myeloid Leukemia280
- Hepatocellular Carcinoma259
- Solid Tumor246
- Advanced Solid Tumor230
- Head and Neck Cancer227
- Cervical Cancer225
- Endometrial Cancer213
- Advanced Solid Tumors209
- Esophageal Cancer190
Leading sponsors
- M.D. Anderson Cancer Center458
- Fudan University306
- National Cancer Institute (NCI)294
- Memorial Sloan Kettering Cancer Center290
- Sun Yat-sen University275
- Mayo Clinic237
- City of Hope Medical Center146
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences145
- AstraZeneca132
- Ruijin Hospital129
Where studies are running
- California1,399
- Texas636
- Arizona505
- Florida438
- Alabama431
- New York405
- Massachusetts342
- Maryland329
- New Jersey275
- Pennsylvania234
Recruiting studies20,349 total
- NCT04913285RecruitingPhase 1
KIN-2787 for advanced solid tumors with BRAF or NRAS mutations
This trial tests a new drug, KIN-2787, for people with advanced solid tumors that have specific changes (mutations) in the BRAF or NRAS genes. The drug is designed to target these changes and may help shrink or control the tumor.
Los Angeles, CaliforniaAges 18 years+ - NCT04894643Recruiting
Pre-surgery proton radiation plus chemo for borderline pancreatic cancer
This trial tests whether giving proton radiation and chemotherapy before surgery can shrink or control “borderline resectable” pancreatic cancer so it can be removed more effectively. It may help by improving treatment response while planning for surgery afterward.
Wiener Neustadt, Lower AustriaAges 18 years+ - NCT04864054RecruitingPhase 1/Phase 2
Study T-cell therapy for advanced liver cancer
This trial tests a custom immune-cell treatment made to target a marker (GPC3) found on some liver cancers. It’s for adults with advanced HCC whose cancer has worsened after standard treatment or who couldn’t tolerate it.
Duarte, CaliforniaAges 18 years+ - NCT04855435RecruitingPhase 1
Study drug for advanced melanoma and other solid tumors
This Phase 1 trial studies a new experimental immunotherapy (MBS8) for people with advanced solid tumors, focusing first on safety and early signs of benefit. Depending on your cancer type and past treatments, you may receive MBS8 alone or combined with pembrolizumab.
HerlevAges 18 years+ - NCT04910685RecruitingPhase 2/Phase 3
BLU-263 for indolent mast cell disease with symptom control
This trial tests BLU-263, a study medicine, against placebo (inactive treatment) to see if it improves symptoms in people with indolent systemic mastocytosis. It also checks safety and how well the dose is tolerated before and during treatment.
Birmingham, AlabamaAges 18 years+ - NCT04872478RecruitingPhase 1
Early-phase drug safety and dosing study for relapsed blood cancers
This Phase 1 trial tests MRX-2843 in teenagers and adults whose leukemia has come back or did not respond to prior treatment. The main goals are to find safe dosing and learn how the body processes the drug.
Atlanta, GeorgiaAges 12 years+ - NCT04915495Enrolling by invitation
Cervical scan test to find high-risk abnormal cervix cells
This study checks whether an advanced cervical scanning test (LuViva) can better identify people who may have serious precancer or early cancer of the cervix. You may be asked to have the scan around the time you are already scheduled for a colposcopy because your screening results were concerning.
Birmingham, AlabamaAges 18 years+ - NCT04868604RecruitingPhase 1/Phase 2
Copper PSMA scan and treatment for prostate cancer in men on low testosterone
This trial tests a PSMA-targeted copper medicine used after a special PSMA PET/CT scan to find and treat prostate cancer that has spread. It’s for men whose testosterone is already very low and whose cancer is growing despite hormone-blocking medicines like enzalutamide or abiraterone.
Stanford, CaliforniaAges 18 years+ - NCT04906434RecruitingPhase 1
Study of ABSK-011 for advanced solid tumors
This early-phase study tests how safe ABSK-011 is, what side effects it causes, and how the body processes the drug. It may help certain patients with advanced solid cancers (including some liver cancer cases) whose tumors have specific test results.
Phoenix, ArizonaAges 18–75 - NCT04900818RecruitingPhase 1
Givastomig for advanced solid cancers, including gastric and pancreas
This Phase 1 trial tests how safe and effective givastomig (TJ033721) is for advanced or metastatic solid tumors. It may help people whose cancer has grown despite standard treatment, or—if in the combination parts—specific cancers that meet certain lab test and tumor-marker requirements.
Orange, CaliforniaAges 18 years+ - NCT04910568RecruitingPhase 1
Study of cevostamab for people with returning or hard-to-treat myeloma
This trial tests a new drug called cevostamab for people whose multiple myeloma has come back or stopped responding to treatment. It aims to see if the drug is safe and how well it works.
Duarte, CaliforniaAges 18 years+ - NCT04891198RecruitingPhase 2
Envafolimumab for advanced cancers after other treatments
This trial tests envafolimumab, an immune therapy given alone, in people with advanced solid tumors that can’t be removed by surgery or have spread. It’s for patients whose cancer has grown despite (or they couldn’t tolerate) standard treatment, and it aims to find whether this drug can shrink tumors or slow growth.
BeijingAges 18 years+ - NCT04866641RecruitingPhase 1
Early safety study of T-1201 for advanced solid tumors
This Phase 1 study tests how safe T-1201 (an injection) is in people with advanced solid tumors that are not responding to standard treatment. It mainly looks at side effects and tolerability, and it may offer a treatment option if other options are no longer working.
Kaohsiung CityAges 20 years+ - NCT04916613RecruitingPhase 3
ADT plus darolutamide for vulnerable newly metastatic prostate cancer
This trial studies whether adding darolutamide to standard hormone therapy (ADT) helps men with newly diagnosed metastatic prostate cancer who are physically vulnerable. It aims to control the cancer better while checking safety and how well treatment is tolerated in this group.
CharleroiAges 18 years+ - NCT04901234RecruitingPhase 2
Adaptive radiation for advanced throat cancer
This study tests an approach called “adaptive radiotherapy,” where the radiation plan may be adjusted based on how your tumor and anatomy look during treatment. It is for adults with biopsy-proven oropharyngeal (throat) squamous cell carcinoma who are planning curative radiation, with or without chemotherapy.
MelbourneAges 18 years+ - NCT04914091Recruiting
Study comfort and medication use after CAR-T therapy
This study looks at quality of life and how medicines are used for people who are getting CAR-T cell therapy for DLBCL. It aims to better understand what helps patients feel and function during follow-up after treatment.
Pierre-BéniteAges 18 years+ - NCT04916990Recruiting
Care program for rural adults with several lung and head cancers
This study looks at how to improve care for adults with certain cancers who live in rural areas and may face access problems. It mainly focuses on people receiving cancer treatment at specific Colorado-area hospitals, and who are uninsured or underinsured.
Aurora, ColoradoAges 18–99 - NCT04879121RecruitingPhase 2
Larotrectinib for tumors with extra NTRK gene copies
This trial studies larotrectinib, a targeted medicine, in people with solid tumors that have extra copies (amplification) of the NTRK1, NTRK2, or NTRK3 gene. It’s for cancers that have already been treated with standard options or where standard options are unlikely to help.
Houston, TexasAges 16 years+ - NCT04915248RecruitingPhase 2
Study of daratumumab, bortezomib, and dexamethasone for plasmablastic lymphoma
This trial tests how well a combination of daratumumab, bortezomib, and dexamethasone works in people with plasmablastic lymphoma that has returned or did not respond to prior treatment. It aims to shrink measurable tumors and improve outcomes, including for some people living with HIV.
Ancona, AnconaAges 18 years+ - NCT04899908RecruitingPhase 2
Brain radiation with or without gadolinium nanoparticles for brain metastases
This trial tests whether adding tiny gadolinium-containing nanoparticles to standard brain radiation can better control brain metastases from certain cancers. It is for people with tumors that have grown after immunotherapy, are from certain cancers (like melanoma, GI, or HER2+ breast), are cystic, are large, or have come back after prior radiation.
Boston, MassachusettsAges 18 years+ - NCT04859465RecruitingPhase 2
Paclitaxel plus doxorubicin for advanced, unresectable angiosarcoma
This Phase 2 trial tests a chemotherapy combination (paclitaxel and liposomal doxorubicin) for people with advanced angiosarcoma that cannot be removed by surgery. It is meant for cases where standard treatment either did not work or was too hard to tolerate, and it aims to shrink tumors and control the disease.
Guangzhou, GuangdongAges 18–70 - NCT04857502RecruitingEarly Phase 1
Tracking prostate cancer spread before lymph node surgery
This early study uses a special imaging tracer to show where prostate cancer has spread in the pelvic lymph nodes. It may help doctors better understand how well certain scans guide surgical removal of affected lymph nodes.
Los Angeles, CaliforniaAges Any age - NCT04883437RecruitingPhase 2
Acalabrutinib plus obinutuzumab for slow-growing lymphoma
This Phase 2 study tests two medicines together—acalabrutinib and obinutuzumab—in people with previously untreated, slow-growing B-cell lymphomas. It aims to shrink the lymphoma and improve disease control, especially when tumor burden is low or when standard first treatments aren’t suitable.
Atlanta, GeorgiaAges 18 years+ - NCT04900623RecruitingPhase 2
Using HPV blood test to guide treatment for HPV throat cancer
This Phase 2 study tests a “risk-adapted” treatment plan for HPV-related throat cancer, using an HPV DNA blood test to help decide how treatment is done. If your baseline blood test shows detectable HPV DNA, the study may help tailor therapy to your risk and potentially improve outcomes while limiting unnecessary treatment.
Boston, MassachusettsAges 22 years+
Common questions
- How many cancer clinical trials are recruiting?
- Clin2 is tracking 20,349 recruiting oncology studies from the U.S. registry right now, out of 31,598 we cover in this area in total.
- What does “Cancer” cover here?
- Studies of cancers and tumors of every type and site, from prevention to treatment. We group each study into cancer based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a cancer trial near me?
- Use the search to filter cancer studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.